Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

Ou, S. H., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., Camidge, D. R., Solomon, B. J., Maki, R. G., Bang, Y. J., Kim, D. W., Christensen, J., Tan, W., Wilner, K. D., Salgia, R., Iafrate, A. J. (May 2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol, 6 (5). pp. 942-6. ISSN 1556-1380 (Electronic)1556-0864 (Linking)

Abstract

Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

Item Type: Paper
Uncontrolled Keywords: Aged Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Bevacizumab Carboplatin/administration & dosage Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology Deoxycytidine/administration & dosage/analogs & derivatives Epithelial-Mesenchymal Transition/*drug effects Female *Gene Amplification Humans Protein Kinase Inhibitors/therapeutic use Proto-Oncogene Proteins c-met/*genetics Pyrazoles/*therapeutic use Pyridines/*therapeutic use Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors Receptors, Growth Factor/*genetics Treatment Outcome
Subjects: diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > cancer types > lung cancer
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: May 2011
Date Deposited: 21 Oct 2016 15:17
Last Modified: 21 Oct 2016 15:17
Related URLs:
URI: https://repository.cshl.edu/id/eprint/33723

Actions (login required)

Administrator's edit/view item Administrator's edit/view item